Research Update

Cambridge Antibody Tech Group PLC
30 May 2003



03/CAT/14

FOR IMMEDIATE RELEASE

10.30 BST, 05.30 EST,  Friday 30 May 2003


For further information contact:
Cambridge Antibody Technology            Weber Shandwick Square Mile (Europe)
Tel: [phone]                Tel: [phone]
John Aston, Chief Financial Officer      Rachel Lankester
Rowena Gardner, Director of Corporate    Kevin Smith
Communications
                                         BMC Communications/The Trout Group (USA)
                                         Tel: [phone]
                                         Brad Miles, ext 17 (media)
                                         Brandon Lewis, ext.15 (investors)



CAMBRIDGE ANTIBODY TECHNOLOGY REPORTS ANNOUNCEMENT FROM ABBOTT LABORATORIES
REGARDING HUMIRATM AND ABT-874



Cambridge, UK...  Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG)
today acknowledges the announcement made by Abbott Laboratories at a meeting
held yesterday for investors and financial analysts.

Abbott announced that it has raised its 2003 sales expectations for HUMIRATM
from more than $200 million to $250 million. Abbott also announced development
progress with ABT-874 (formerly J695), discussing promising Phase II Crohn's
disease data for ABT-874 and plans for a Phase II study in multiple sclerosis in
the first half of 2004.

HUMIRA was isolated and optimised by CAT in collaboration with Abbott, and CAT
will receive royalties on the sales of HUMIRA. ABT-874 was also isolated and
optimised by CAT and Abbott, and was licensed by CAT to Abbott under the same
1995 agreement between CAT and Knoll Aktiengesellschaft (now a subsidiary of
Abbott Laboratories). CAT receives development milestone payments and will
receive royalties on sales of ABT-874.





- ENDS -



Notes to Editors

Cambridge Antibody Technology (CAT):

•      CAT is a UK-based biotechnology company using its proprietary
technologies and capabilities in human monoclonal antibodies for drug discovery
and drug development. Based near Cambridge, England, CAT currently employs
around 290 people.

•      CAT is a leader in the discovery and development of human therapeutic
antibodies and has an advanced proprietary platform technology for rapidly
isolating human monoclonal antibodies using phage display systems. CAT has
extensive phage antibody libraries, currently incorporating more than 100
billion distinct antibodies. These libraries form the basis for the Company's 
strategy to develop a portfolio of antibody-based drugs.

•      HumiraTM is the leading CAT-derived antibody. Six other CAT-derived human
therapeutic antibodies are at various stages of clinical trials.

•      CAT has alliances with a large number of pharmaceutical and biotechnology
companies to discover, develop and commercialise human monoclonal antibody-based
products. CAT has also licensed its proprietary human phage antibody libraries
to several companies for target validation and drug discovery. CAT's
collaborators include: Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome
Sciences, Merck & Co, Pfizer and Wyeth Research.

•       CAT is listed on the London Stock Exchange and on NASDAQ since June
2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering
in March 2000.



Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995:

This press release contains statements about Cambridge Antibody Technology Group
plc ("CAT") that are forward looking statements. All statements other than
statements of historical facts included in this press release may be forward
looking statements within the meaning of Section 21E of the Securities Exchange
Act of 1934. These forward looking statements are based on numerous assumptions
regarding CAT's present and future business strategies and the
environment in which CAT will operate in the future. Certain factors that could
cause CAT's actual results, performance or achievements to differ
materially from those in the forward looking statements include: market
conditions, CAT's ability to enter into and maintain collaborative
arrangements, success of product candidates in clinical trials, regulatory
developments and competition.


                      This information is provided by RNS
            The company news service from the London Stock Exchange